Scientific Session

Risk of Major Adverse Cardiovascular Events with Tofacitinib versus Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis with or Without a History of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis from ORAL Surveillance

Speaker(s)

• 

  Maya Buch, MD, PhD

  University of Manchester
  Manchester, United Kingdom

  Disclosure: Disclosure(s): No financial relationships with ineligible companies to disclose